Literature DB >> 31130561

Interleukin-1beta Inhibition Attenuates Vasculitis in a Mouse Model of Kawasaki Disease.

Yoshiaki Hashimoto1, Ryuji Fukazawa1, Noriko Nagi-Miura2, Naohito Ohno2, Nobuko Suzuki1, Yasuhiro Katsube1, Mitsuhiro Kamisago1, Miharu Akao1, Makoto Watanabe1, Koji Hashimoto1, Kanae Tsuno1, Ryosuke Matsui1, Yasuhiko Itoh1.   

Abstract

BACKGROUND: Kawasaki disease (KD), a systemic vasculitis, is suspected to be related to abnormalities in innate immunity. Based on the important role of IL-1 signaling in innate immunity, we investigated the effects of an anti-IL-1β antibody using a Candida albicans water-soluble fraction (CAWS)-induced mouse model of KD.
METHODS: CAWS (0.5 mg/mouse) was injected intraperitoneally into 5-week-old DBA/2 mice on five consecutive days. An anti-Murine IL-1β antibody (01BSUR) was administered at various doses (2.5, 5.0, and 10.0 mg/kg) and time points (2 days before, same day, and 2, 5, 7, and 14 days after CAWS administration). After 4 weeks, vasculitis in the aortic root was investigated histologically. Cytokines including IL-1β, -6, -10, and TNF-α were also measured.
RESULTS: Groups administered 01BSUR at all doses showed a significant reduction in the area of vasculitis. In addition, 01BSUR inhibited vasculitis until 7 days after CAWS administration. In the analysis of various time points, the level of IL-6 was lower in all groups compared to the CAWS only group, but the levels of IL-1β, TNFα, and IL-10 were lower when 01BSUR was administered before CAWS. On the other hand, TNFα and IL-10 levels were restored when 01BSUR was administered after CAWS, suggesting that 01BSUR may have additional effects beyond blocking IL-1β signaling.
CONCLUSIONS: The anti-IL-1β antibody significantly attenuated CAWS-induced vasculitis. The mechanism of inhibiting vasculitis is thought to include inhibition of the IL-1β pathway and additional effects beyond blocking IL-1β signaling.

Entities:  

Keywords:  Kawasaki disease; Kawasaki disease model mouse; cytokine profile; interleukin-10; interleukin-1beta

Mesh:

Substances:

Year:  2019        PMID: 31130561     DOI: 10.1272/jnms.JNMS.2019_86-206

Source DB:  PubMed          Journal:  J Nippon Med Sch        ISSN: 1345-4676            Impact factor:   0.920


  5 in total

Review 1.  Kawasaki disease: pathophysiology and insights from mouse models.

Authors:  Magali Noval Rivas; Moshe Arditi
Journal:  Nat Rev Rheumatol       Date:  2020-05-26       Impact factor: 20.543

2.  Inhibition of IL-6 in the LCWE Mouse Model of Kawasaki Disease Inhibits Acute Phase Reactant Serum Amyloid A but Fails to Attenuate Vasculitis.

Authors:  Rebecca A Porritt; Carol Chase Huizar; Edward J Dick; Shyamesh Kumar; Renee Escalona; Angela C Gomez; Stefani Marek-Iannucci; Magali Noval Rivas; Jean Patterson; Thomas G Forsthuber; Moshe Arditi; Mark Gorelik
Journal:  Front Immunol       Date:  2021-04-09       Impact factor: 7.561

3.  Kawasaki Disease-like Vasculitis Facilitates Atherosclerosis, and Statin Shows a Significant Antiatherosclerosis and Anti-Inflammatory Effect in a Kawasaki Disease Model Mouse.

Authors:  Yusuke Motoji; Ryuji Fukazawa; Ryosuke Matsui; Noriko Nagi-Miura; Yasuo Miyagi; Yasuhiko Itoh; Yosuke Ishii
Journal:  Biomedicines       Date:  2022-07-26

4.  CDCP1 on Dendritic Cells Contributes to the Development of a Model of Kawasaki Disease.

Authors:  Yu Lun; Nozha Borjini; Noriko N Miura; Naohito Ohno; Nora G Singer; Feng Lin
Journal:  J Immunol       Date:  2021-06-07       Impact factor: 5.426

5.  Molecular MR-Imaging for Noninvasive Quantification of the Anti-Inflammatory Effect of Targeting Interleukin-1β in a Mouse Model of Aortic Aneurysm.

Authors:  Julia Brangsch; Carolin Reimann; Jan Ole Kaufmann; Lisa Christine Adams; David Onthank; Christa Thöne-Reineke; Simon Robinson; Marco Wilke; Michael Weller; Rebecca Buchholz; Uwe Karst; Rene Botnar; Bernd Hamm; Marcus Richard Makowski
Journal:  Mol Imaging       Date:  2020 Jan-Dec       Impact factor: 4.488

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.